Atypical	O
fractures	O
:	O
After	O
approving	O
the	O
drug	O
on	O
8	DATE
July	DATE
2009	DATE
,	O
the	O
EuropeanMedicines	O
Agency	O
conducted	O
a	O
class	O
review	O
of	O
all	O
bisphosphonates	O
,	O
includingZoledronate	O
,	O
after	O
several	O
cases	O
of	O
atypical	O
fractures	O
were	O
reported	O
.	O
In2008	O
,	O
the	O
EMA	ORGANIZATION
's	O
Pharmacovigilance	ORGANIZATION
Working	ORGANIZATION
Party	ORGANIZATION
noted	O
that	O
alendronicacid	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
atypical	O
fracture	O
of	O
the	O
femurthat	O
developed	O
with	O
low	O
or	O
no	O
trauma	O
.	O
In	O
April	DATE
2010	DATE
,	O
the	O
PhVWP	O
noted	O
thatfurther	O
data	O
from	O
both	O
the	O
published	O
literature	O
and	O
post-marketing	O
reportswere	O
now	DATE
available	O
which	O
suggested	O
that	O
atypical	O
stress	O
fractures	O
of	O
the	O
femurmay	O
be	O
a	O
class	O
effect	O
.	O
The	O
European	ORGANIZATION
Medicines	ORGANIZATION
Agency	ORGANIZATION
then	O
reviewed	O
all	O
casereports	O
of	O
stress	O
fractures	O
in	O
patients	O
treated	O
with	O
bisphosphonates	O
,	O
relevantdata	O
from	O
the	O
published	O
literature	O
,	O
and	O
data	O
provided	O
by	O
the	O
companies	O
whichmarket	O
bisphosphonates	O
.	O
The	O
Agency	O
recommended	O
that	O
doctors	O
who	O
prescribebisphosphonate-containing	O
medicines	O
should	O
be	O
aware	O
that	O
atypical	O
fracturesmay	O
occur	O
rarely	O
in	O
the	O
femur	O
,	O
especially	O
after	O
long-term	O
use	O
,	O
and	O
thatdoctors	O
who	O
are	O
prescribing	O
these	O
medicines	O
for	O
the	O
prevention	O
or	O
treatment	O
ofosteoporosis	O
should	O
regularly	O
review	O
the	O
need	O
for	O
continued	O
treatment	O
,	O
especially	O
after	O
five	NUMBER
or	O
more	O
years	DURATION
of	O
use	O
.	O
